Efficacy and immune correlates of the SRA737 plus LDG regimen in combination with anti-PD-L1 in an SCLC model

Bookmark and Share
Published: 15 Apr 2019
Views: 1832
Dr Triparna Sen - MD Anderson Cancer Center, Houston, Texas

Dr Triparna Sen speaks to ecancer at the 2019 American Association for Cancer Research (AACR) meeting about results from a study looking at the efficacy and correlates of immunity of the combination treatment involving CHK1 inhibitor SRA737 plus low dose gemcitabine with anti-PDL1 in a model of small cell lung cancer (SCLC).

She explains that SCLC is very good at hiding itself from the immune system causing most of the immunotherapy drugs so far to have modest benefit.

Dr Sen reports that this combination with immune checkpoint blockade and DNA damage repair completely regressed tumours in mouse models.